Pfizer Inc. (NYSE:PFE) Shares Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC grew its holdings in Pfizer Inc. (NYSE:PFE) by 3,885.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,899,435 shares of the biopharmaceutical company’s stock after purchasing an additional 1,851,772 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Pfizer were worth $53,146,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Gilbert & Cook Inc. raised its stake in Pfizer by 3.8% in the 4th quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 945 shares during the last quarter. Gryphon Financial Partners LLC raised its position in shares of Pfizer by 43.7% in the fourth quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock valued at $861,000 after buying an additional 8,194 shares during the last quarter. Principal Securities Inc. purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $2,393,000. Kovitz Investment Group Partners LLC boosted its position in Pfizer by 18.8% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 168,767 shares of the biopharmaceutical company’s stock worth $4,859,000 after acquiring an additional 26,706 shares during the last quarter. Finally, Calton & Associates Inc. purchased a new stake in Pfizer in the 4th quarter worth approximately $334,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PFE has been the topic of several analyst reports. Barclays raised their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Wells Fargo & Company lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, August 19th. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Stock Up 0.2 %

Pfizer stock traded up $0.05 during midday trading on Friday, hitting $28.56. 31,214,484 shares of the company were exchanged, compared to its average volume of 38,328,773. The company has a market cap of $161.84 billion, a PE ratio of -476.00, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $34.64. The company’s fifty day moving average price is $29.06 and its 200-day moving average price is $28.05. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.67 earnings per share. On average, research analysts predict that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.88%. The ex-dividend date of this dividend was Friday, July 26th. Pfizer’s payout ratio is -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.